About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Tennessee | 519 Studies

Clinical Trials LymphomaTennessee

Lymphoma Clinical Trials in Tennessee

Find 519 clinical trials for lymphoma near Tennessee. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Tennessee

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 161-180 of 519 trials

CompletedA Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma.NCT02213263·Anaheim, California and 422 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

RecruitingA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaThe purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung…NCT03460977·Tucson, Arizona and 84 others

WithdrawnA Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin LymphomaThis study will investigate the safety, pharmacology, and activity of atezolizumab in combination with immunotherapy agents with or without an anti-CD20 agent (i.e., obinutuzumab)…NCT03369964·Duarte, California and 1 other

CompletedLenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaThis phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned…NCT02568553·Birmingham, Alabama and 23 others

CompletedTreatment of Burkitt Lymphoma/Leukemia and B Large Cell NHLThis is a pilot study to demonstrate that the modified LMB-89 treatment regimen for children with newly diagnosed small noncleaved cell NHL, large cell NHL (B-cell), and B-cell…NCT00187161·Memphis, Tennessee

TerminatedAn Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced MalignanciesThis is an open-label study of INCB047986 given to two distinct groups of patients (Group 1 and Group 2) with advanced malignancies.NCT01929941·Atlanta, Georgia and 2 others

RecruitingA Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomaThis is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in…NCT07123454·Irvine, California and 22 others

Active not recruitingA Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesThis study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies.NCT04072458·Augusta, Georgia and 4 others

CompletedA Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCLThis is a multicenter, open-label, dose-finding study of venetoclax administered orally in combination with rituximab (R) or obinutuzumab (G) and standard doses of…NCT02055820·Fullerton, California and 51 others

CompletedA Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin LymphomaThis study examined the effects of predefined 2-week duvelisib dose holidays on tumor responses and safety/tolerability.NCT04038359·Fort Myers, Florida and 27 others

CompletedA Safety and Tolerability Study of PCI-24781 in Subjects With CancerThe purpose of this study is to determine the long-term (\> 6 months) safety of PCI 24781 PO in subjects with lymphoma.NCT01149668·Chicago, Illinois and 4 others

CompletedStudy Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory LymphomaThe primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.NCT00061672·Phoenix, Arizona and 13 others

Active not recruitingA Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed…NCT03162536·Scottsdale, Arizona and 9 others

CompletedProleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade…NCT00045864·Tucson, Arizona and 32 others

TerminatedGamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaThis phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with…NCT01088763·Palo Alto, California and 11 others

TerminatedNovel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular LymphomaFirst study, at multiple clinical centers, exploring the effects of different combinations of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell…NCT02031419·Stanford, California and 15 others

CompletedPilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic MalignanciesThe prognosis of pediatric patients with hematologic malignancies whose disease is primarily refractory or those who experience a chemotherapy resistant bone marrow relapse is…NCT00697671·Memphis, Tennessee

CompletedA Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological MalignanciesTo assess safety and tolerability, describe the dose-limiting toxicities, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered…NCT03106428·Los Angeles, California and 13 others

Active not recruitingStudying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or LymphomaThis phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with…NCT05602194·Birmingham, Alabama and 227 others

UnknownDenileukin Diftitox in Treating Patients With Non-Hodgkin's LymphomaRATIONALE: Biological therapies such as denileukin diftitox may be able to deliver cancer-killing substances directly to non-Hodgkin's lymphoma cells.NCT00026429·Pomona, California and 5 others

PreviousPage 9 of 26Next

Other Conditions in Tennessee

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia